TCF7L2 genetic defect and type 2 diabetes

Current Diabetes Reports

Volumn 8, Issue 2, 2008, Pages 149-155

  Cauchi, Stéphane ^b   Froguel, Philippe ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; EXOSTOSIN 2; GLUCAGON LIKE PEPTIDE 1; HOMEODOMAIN PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE 26; MEMBRANE PROTEIN; METFORMIN; NEUROGENIN 3; POTASSIUM CHANNEL; SOMATOMEDIN BINDING PROTEIN 2; SULFONYLUREA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG; WNT PROTEIN; T CELL FACTOR 4; T CELL FACTOR PROTEIN;

ADIPOCYTE; ADIPOGENESIS; ALLELE; BODY MASS; CAUCASIAN; CELL DIFFERENTIATION; ETHNIC GROUP; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INDIVIDUALIZATION; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATIENT CARE; PHARMACOGENETICS; POPULATION GENETICS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE; WEIGHT CHANGE; ANIMAL; BODY WEIGHT; GENETICS; PHYSIOLOGY;

ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 44849083863     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0026-x     Document Type: Review

References (86)

1. Deeb SS, Fajas L, Nemoto M, et al.: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
2. Altshuler D, Hirschhorn JN, Klannemark M, et al.: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26:76-80.
3. Hani EH, Boutin P, Durand E, et al.: Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/ BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia 1998, 41:1511-1515.
4. Nielsen EM, Hansen L, Carstensen B, et al.: The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003, 52:573-577.
5. Barroso I, Gurnell M, Crowley VE, et al.: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
6. Gloyn AL, Pearson ER, Antcliff JF, et al.: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004, 350:1838-1849.
7. Tsuchiya T, Schwarz PE, Bosque-Plata LD, et al.: Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol Genet Metab 2006, 89:174-184.
8. Osawa H, Yamada K, Onuma H, et al.: The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 2004, 75:678-686.
9. Silander K, Mohlke KL, Scott LJ, et al.: Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes. Diabetes 2004, 53:1141-1149.
10. Winckler W, Weedon MN, Graham RR, et al.: Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 2007, 56:685-693.
11. Vasseur F, Helbecque N, Lobbens S, et al.: Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 2005, 48:892-899.
12. Holmkvist J, Cervin C, Lyssenko V, et al.: Common variants in HNF-1 alpha and risk of type 2 diabetes. Diabetologia 2006, 49:2882-2891.
13. Meyre D, Bouatia-Naji N, Tounian A, et al.: Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet 2005, 37:863-867.
14. Grant SF, Thorleifsson G, Reynisdottir I, et al.: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38:320-323.
15. Scott LJ, Bonnycastle LL, Willer CJ, et al.: Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006, 55:2649-2653.
16. Groves CJ, Zeggini E, Minton J, et al.: Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006, 55:2640-2644.
17. Saxena R, Gianniny L, Burtt NP, et al.: Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55:2890-2895.
18. Cauchi S, Meyre D, Dina C, et al.: Transcription factor TCF7L2 genetic study in the French population: expression in human {beta}-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006, 55:2903-2908.
19. van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova. A, et al.: Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 2007, 50:59-62.
20. Humphries SE, Gable D, Cooper JA, et al.: Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women. J Mol Med 2006, 84:1-10.
21. Damcott CM, Pollin TI, Reinhart LJ, et al.: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006, 55:2654-2659.
22. Florez JC, Jablonski KA, Bayley N, et al.: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006, 355:241-250.
23. Zhang C, Qi L, Hunter DJ, et al.: Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes 2006, 55:2645-2648.
24. Marzi C, Huth C, Kolz M, et al.: Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res 2007, 39:46-52.
25. Melzer D, Murray A, Hurst AJ, et al.: Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med 2006, 4:34.
26. Mayans S, Lackovic K, Lindgren P, et al.: TCF7L2 polymorphisms are associated with type 2 diabetes in northern Sweden. Eur J Hum Genet 2007, 15:342-346.
27. Helgason A, Palsson S, Thorleifsson G, et al.: Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007, 39:218-225.
28. Lehman DM, Hunt KJ, Leach RJ, et al.: Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans. Diabetes 2007, 56:389-393.
29. Chandak GR, Janipalli CS, Bhaskar S, et al.: Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 2007, 50:63-67.
30. Horikoshi M, Hara K, Ito C, et al.: A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 2007, 50:747-751.
31. Hayashi T, Iwamoto Y, Kaku K, et al.: Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population. Diabetologia 2007, 50:980-984.
32. Cauchi S, El Achhab Y, Choquet H, et al.: TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med 2007, 85:777-782.
33. Barroso I, Luan J, Sandhu MS, et al.: Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 2006, 49:501-505.
34. Gloyn AL, Weedon MN, Owen KR, et al.: Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003, 52:568-572.
35. Love-Gregory L, Wasson J, Lin J, et al.: E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of type II diabetes in Caucasians as the PPARgamma Pro12Ala variant. Diabetologia 2003, 46:136-137.
36. Weedon MN, Schwarz PE, Horikawa Y, et al.: Metaanalysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 2003, 73:1208-1212.
37. Weedon MN, Owen KR, Shields B, et al.: A largescale association analysis of common variation of the HNF1alpha gene with type 2 diabetes in the U.K. Caucasian population. Diabetes 2005, 54:2487-2491.
38. Weedon MN, Shields B, Hitman G, et al.: No evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 U.K. Caucasians. Diabetes 2006, 55:3175-3179.
39. Qi L, van Dam RM, Meigs JB, et al.: Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006, 15:1914-1920.
40. Huth C, Heid IM, Vollmert C, et al.: IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006, 55:2915-2921.
41. Cauchi S, Meyre D, Choquet H, et al.: TCF7L2 variation predicts hyperglycemia incidence in a French general population: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 2006, 55:3189-3192.
42. Ng MC, Tam CH, Lam VK, et al.: Replication and identification of novel variants at TCF7L2 associated with type 2 diabetes in Hong Kong Chinese. J Clin Endocrinol Metab 2007, 92:3733-3737.
43. Chang YC, Chang TJ, Jiang YD, et al.: Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes 2007, 56:2631-2637.
44. Frazer KA, Ballinger DG, Cox DR, et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
45. Sladek R, Rocheleau G, Rung J, et al.: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
46. Zeggini E, Weedon MN, Lindgren CM, et al.: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316:1336-1341.
47. Scott LJ, Mohlke KL, Bonnycastle LL, et al.: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
48. Saxena R, Voight BF, Lyssenko V, et al.: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316:1331-1336.
49. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al.: A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007, 39:770-775.
50. Barker N, Morin PJ, Clevers H: The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res 2000, 77:1-24.
51. Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
52. Munemitsu S, Albert I, Souza B, et al.: Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A 1995, 92:3046-3050.
53. Rubinfeld B, Souza B, Albert I, et al.: Association of the APC gene product with beta-catenin. Science 1993, 262:1731-1734.
54. Su LK, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 1993, 262:1734-1737.
55. Behrens J, von Kries JP, Kuhl M, et al.: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638-642.
56. Korinek V, Barker N, Morin PJ, et al.: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
57. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
58. Papadopoulou S, Edlund H: Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 2005, 54:2844-2851.
59. Apelqvist A, Ahlgren U, Edlund H: Sonic hedgehog directs specialised mesoderm differentiation in the intestine and pancreas. Curr Biol 1997, 7:801-804.
60. Thomas MK, Rastalsky N, Lee JH, Habener JF: Hedgehog signaling regulation of insulin production by pancreatic beta-cells. Diabetes 2000, 49:2039-2047.
61. Nusse R: Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 2003, 130:5297-5305.
62. Kalderon D: Similarities between the hedgehog and Wnt signaling pathways. Trends Cell Biol 2002, 12:523-531.
63. Luo Y, Cai J, Xue H, et al.: SDF1alpha/CXCR4 signaling stimulates beta-catenin transcriptional activity in rat neural progenitors. Neurosci Lett 2006, 398:291-295.
64. Cauchi S, Vaxillaire M, Choquet H, et al.: No major contribution of TCF7L2 sequence variants to maturity onset of diabetes of the young (MODY) or neonatal diabetes mellitus in French white subjects. Diabetologia 2007, 50:214-216.
65. Duval A, Rolland S, Tubacher E, et al.: The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 2000, 60:3872-3879.
66. Cauchi S, Choquet H, Gutiérrez-Aguilar R, et al.: Effects of TCF7L2 polymorphisms on obesity in European populations. Obesity (Silver Spring) 2008, In press.
67. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al.: Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422.
68. Wang J, Kuusisto J, Vanttinen M, et al.: Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 2007, 50:1192-1200.
69. Watanabe RM, Allayee H, Xiang AH, et al.: Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. Diabetes 2007, 56:1481-1485.
70. Loos RJ, Franks PW, Francis RW, et al.: TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007, 56:1943-1947.
71. Munoz J, Lok KH, Gower BA, et al.: Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 2006, 55:3630-3634.
72. Korinek V, Barker N, Moerer P, et al.: Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998, 19:379-383.
73. Schafer SA, Tschritter O, Machicao F, et al.: Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007, 50:2443-2450.
74. Lyssenko V, Lupi R, Marchetti P, et al.: Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007, 117:2155-2163.
75. Nauck MA, Meier JJ: The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. Diabetologia 2007, 50:2413-2416.
76. Pearson ER, Donnelly LA, Kimber C, et al.: Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56:2178-2182.
77. Ross SE, Hemati N, Longo KA, et al.: Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
78. Cawthorn WP, Heyd F, Hegyi K, Sethi JK: Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ 2007, 14:1361-1373.
79. Bennett CN, Ross SE, Longo KA, et al.: Regulation of Wnt signaling during adipogenesis. J Biol Chem 2002, 277:30998-31004.
80. Cauchi S, Meyre D, Choquet H, et al.: TCF7L2 rs7903146 variant does not associate with smallness for gestational age in the French population. BMC Med Genet 2007, 8:37.
81. Freathy RM, Weedon MN, Bennett A, et al.: Type 2 diabetes TCF7L2 risk genotypes after birth weight: a study of 24,053 individuals. Am J Hum Genet 2007, 80:1150-1161.
82. Butler PC, Meier JJ, Butler AE, Bhushan A: The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007, 3:758-768.
83. Janssens AC, Gwinn M, Valdez R, et al.: Predictive genetic testing for type 2 diabetes. BMJ 2006, 333:509-510.
84. Weedon MN, McCarthy MI, Hitman G, et al.: Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 2006, 3:e374.
85. Yang Q, Khoury MJ, Friedman J, et al.: How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 2005, 34:1129-1137.
86. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.